Literature DB >> 7534291

Identification of a lipopolysaccharide binding domain in CD14 between amino acids 57 and 64.

T S Juan1, E Hailman, M J Kelley, L A Busse, E Davy, C J Empig, L O Narhi, S D Wright, H S Lichenstein.   

Abstract

CD14 is a 55-kDa glycoprotein which binds lipopolysaccharide (LPS) and enables LPS-dependent responses in a variety of cells. Recent limited proteolysis studies have implicated a region in CD14 between amino acids 57 and 64 as being involved in LPS interaction. To specifically assess the importance of this region with respect to LPS binding, we constructed a mutant sCD14 (sCD14 delta 57-64) lacking amino acids 57-64. sCD14 delta 57-64 was isolated from the serum-free conditioned medium of this cell line, and, in all assays, the purified protein failed to recognize LPS or enable LPS-dependent responses in cells. We also demonstrated that the region between amino acids 57 and 64 is required for binding of a neutralizing CD14 mAb, MEM-18. Native polyacrylamide gel electrophoresis assays were used to demonstrate that MEM-18 and LPS compete for the same binding site on CD14. These data strongly suggest that the region spanning amino acids 57-64 binds LPS and that formation of sCD14.LPS complex is required in order for sCD14-mediated responses to occur.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7534291     DOI: 10.1074/jbc.270.10.5219

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation.

Authors:  D Filipp; K Alizadeh-Khiavi; C Richardson; A Palma; N Paredes; O Takeuchi; S Akira; M Julius
Journal:  Proc Natl Acad Sci U S A       Date:  2001-01-16       Impact factor: 11.205

2.  Comparison of lipopolysaccharide-binding functions of CD14 and MD-2.

Authors:  Jun Koraha; Naoko Tsuneyoshi; Masao Kimoto; Jean-Francois Gauchat; Hiroshi Nakatake; Kenji Fukudome
Journal:  Clin Diagn Lab Immunol       Date:  2005-11

Review 3.  C1 inhibitor: biologic activities that are independent of protease inhibition.

Authors:  Alvin E Davis; Shenghe Cai; Dongxu Liu
Journal:  Immunobiology       Date:  2006-12-11       Impact factor: 3.144

4.  Serum antibodies to oral anaerobic bacteria in patients with rheumatoid arthritis.

Authors:  Mesut Ogrendik; Siranus Kokino; Ferda Ozdemir; Philip S Bird; Stephen Hamlet
Journal:  MedGenMed       Date:  2005-06-16

5.  Interaction of human peripheral blood monocytes with apoptotic polymorphonuclear cells.

Authors:  Tomasz P Mikołajczyk; Joanna E Skrzeczyńska-Moncznik; Mirosław A Zarebski; Ewa A Marewicz; Anna M Wiśniewska; Magdalena Dzieba; Jerzy W Dobrucki; Juliusz R Pryjma
Journal:  Immunology       Date:  2009-09       Impact factor: 7.397

Review 6.  Antiendotoxin strategies for the prevention and treatment of septic shock. New approaches and future directions.

Authors:  S M Opal; R L Yu
Journal:  Drugs       Date:  1998-04       Impact factor: 9.546

7.  N-linked glycosylation at Asn3 and the positively charged residues within the amino-terminal domain of the c1 inhibitor are required for interaction of the C1 Inhibitor with Salmonella enterica serovar typhimurium lipopolysaccharide and lipid A.

Authors:  Dongxu Liu; Cort C Cramer; Jennifer Scafidi; Alvin E Davis
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

8.  Soluble CD14 activates monocytic cells independently of lipopolysaccharide.

Authors:  R Landmann; S Link; S Sansano; Z Rajacic; W Zimmerli
Journal:  Infect Immun       Date:  1998-05       Impact factor: 3.441

9.  Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages.

Authors:  P Y Perera; N Qureshi; S N Vogel
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

Review 10.  Receptors, mediators, and mechanisms involved in bacterial sepsis and septic shock.

Authors:  Edwin S Van Amersfoort; Theo J C Van Berkel; Johan Kuiper
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.